Re­gen­eron, GSK see mas­sive spike in Covid-19 mAb de­mand as US de­bates buy­ing more

The Delta vari­ant is busy dri­ving up new Covid-19 cas­es na­tion­wide, ac­cel­er­at­ing de­mand for mon­o­clon­al an­ti­body treat­ments from Re­gen­eron and Glax­o­SmithK­line, which can re­duce hos­pi­tal­iza­tions and deaths if used ap­pro­pri­ate­ly.

Re­gen­eron has seen a dra­mat­ic in­crease in de­mand for its mAb cock­tail of casiriv­imab plus imde­vimab in just the past month. The com­pa­ny has led the mAb field since nab­bing an ear­ly EUA for the drug, which can now be ad­min­is­tered sub­cu­ta­neous­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER